{"id":"NCT01827839","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster","officialTitle":"Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-10","primaryCompletion":"2014-02-10","completion":"2014-11-25","firstPosted":"2013-04-10","resultsPosted":"2017-03-07","lastUpdate":"2018-10-18"},"enrollment":96,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Herpes Zoster"],"interventions":[{"type":"BIOLOGICAL","name":"Herpes Zoster vaccine (GSK1437173A)","otherNames":["HZ/su vaccine"]}],"arms":[{"label":"HZ Group","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' â‰¥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.","primaryOutcome":{"measure":"Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA","timeFrame":"At Month 3","effectByArm":[{"arm":"GSK1437173A Group","deltaMin":74,"sd":null},{"arm":"GSK1437173A Group 50-59 YOA","deltaMin":26,"sd":null},{"arm":"GSK1437173A Group 60-69 YOA","deltaMin":26,"sd":null},{"arm":"GSK1437173A Group >=70 YOA","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":4,"countries":["Canada","Russia"]},"refs":{"pmids":["28068212"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":96},"commonTop":["Pain","Fatigue","Headache","Myalgia","Chills"]}}